Foscarnet-induced crystalline glomerulonephritis with nephrotic syndrome and acute renal failure after kidney transplantation

Transplantation

Volumn 67, Issue 10, 1999, Pages 1376-1378

  Zanetta, Gilbert ^a   Maurice Estepa, Laurence ^b   Mousson, Christiane ^a   Justrabo, Eve ^a   Daudon, Michel ^b   Rifle, Gerard ^a,c   Tanter, Yves ^a,c  

^a DIJON UNIVERSITY HOSPITAL   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

^c HÔPITAL DU BOCAGE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIVIRUS AGENT; AZATHIOPRINE; CORTICOSTEROID; FOSCARNET; FOSFOMYCIN; GANCICLOVIR; IMMUNOSUPPRESSIVE AGENT; THYMOCYTE ANTIBODY; VANCOMYCIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ACUTE KIDNEY FAILURE; ADULT; ARTICLE; CASE REPORT; CYTOMEGALOVIRUS INFECTION; DRUG INDUCED DISEASE; GLOMERULONEPHRITIS; GRAFT REJECTION; HUMAN; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MALE; NEPHROTIC SYNDROME; NEPHROTOXICITY; POSTOPERATIVE INFECTION; PRIORITY JOURNAL;

AIDS-ASSOCIATED NEPHROPATHY; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; FOSCARNET; GLOMERULONEPHRITIS; HUMANS; KIDNEY FAILURE, ACUTE; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; NEPHROTIC SYNDROME;

EID: 0033609380     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199905270-00016     Document Type: Article

References (14)

1. Oberg B. Antiviral effects of phosphonoformate (PFA, foscarnet sodium). Pharmacol Ther 1983; 19: 387.
2. Wagstaff AJ, Bryson HM. Foscarnet: a reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections. Drugs 1994; 48: 199.
3. Ringden O, Lonnqvist B, Paulin T, et al. Pharmacokinetics, safety and preliminary clinical experiences using foscarnet in the treatment of cytomegalovirus infections in bone-marrow and renal transplant recipients. J Antimicrob Chemother 1986; 17: 373.
4. Cacoub P, Deray G, Baumelou A, et al. Acute renal failure induced by foscarnet: 4 cases. Clin Nephrol 1988; 29: 315.
5. Deray G, Martinez F, Katlama C, et al. Foscarnet nephrotoxicity: mechanism, incidence and prevention. Am J Nephrol 1989; 9: 316.
6. Nyberg G, Blohme I, Persson H, Svalander C. Foscarnet-induced tubulointerstitial nephritis in renal transplant patients. Transplant Proc 1990; 22: 2410.
7. Beaufils H, Deray G, Katlama C, et al. Foscarnet and crystals in glomerular capillary lumens. Lancet 1990; 336: 755.
8. Trolliet P, Dijoud F, Cotte L, et al. Crescentic glomerulonephritis and crystals within glomerular capillaries in an AIDS patient treated with foscarnet. Am J Nephrol 1995; 15: 256.
9. Justrabo E, Martin L, Zanetta G, et al. Irreversible glomerular lesions induced by crystal precipitation in a renal transplant after foscarnet therapy for cytomegalovirus infection. Histopathology (in press).
10. Daudon M, Marfisi C, Lacour B, Bader C. Investigation of urinary crystals by Fourier transform infrared microscopy. Clin Chem 1991; 37: 83.
11. Maurice-Estepa L, Hennequin C, Marfisi C, Bader C, Lacour B, Daudon M. Fourier transform infrared microscopy identification of crystal deposits in tissues. Am J Clin Pathol 1996; 105: 576.
12. Maurice-Estepa L, Daudon M, Katlama C, et al. Identification of crystals in kidney from AIDS patients treated with foscarnet. Am J Kidney Dis 1998; 32: 392.
13. Churg J, Cotran RS, Sinniah R, Sakaguchil H, Sobin LH. Renal disease: classification and atlas of tubulo-interstitial disease, chapter 11. New York: Igaku Shoin Medical Publishers, 1985: 157.
14. Churg J, Sobin LH. Renal disease: classification and atlas of glomerular diseases, chapter 11. New York: Igaku Shoin Medical Publishers, 1982: 157.